HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Onconova Therapeutics (NASDAQ:ONTX) and maintained a price target of $11.
August 11, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Onconova Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $11.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Onconova Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100